Abstract
The identification of the specific cause in every patient has important clinical implications, because ischemic stroke is an etiologically heterogeneous disease. The Trial of Org 10172 in Acute Stroke Treatment （TOAST） classification can be used to define the etiology of stroke. However, TOAST classification can not be completed timely on admission of patients with acute stroke, which has impacted early guidance of clinical treatment, This article reviews the biological markers of early differential-diagnostic significance of the TOAST classification. Key words: Stroke; Brain ischemia; Biological markers; Natriuretic peptide, brain; C- reactive protein; Fibrin fibrinogen degradation products; Lipoprotein（a）
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
